CooperCompanies posts $1.07bn Q3 revenue amid CVI inventory drag

CooperCompanies hit $1.07bn in Q3 revenue but warned a US channel inventory reduction at CooperVision will weigh into the fourth quarter.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A brightly lit, automated warehouse with rows of tall metal racks filled with storage crates, and a central conveyor system carrying more crates down an aisle towards large windows at the far end.

CooperCompanies (Nasdaq: COO) reported third-quarter revenue of $1.066 billion for the period ended 31 July 2026, up 1% year-on-year on both a reported and organic basis, as strong fertility growth at its CooperSurgical division was partially offset by a deliberate drawdown of US channel inventory at CooperVision.

Non-GAAP diluted earnings per share came in at $1.15, a 4% increase on the prior-year quarter. GAAP diluted EPS of $2.24 was significantly higher than the $0.49 recorded a year ago, though the uplift was almost entirely driven by a one-off $307.2 million discrete tax benefit following the UK's HMRC closing its examination of the company's 2021 intellectual property transfer with no proposed adjustments. Free cash flow surged 66% to $273.0 million.

Division performance

CooperVision, the company's contact lens business, generated revenue of $717.0 million, flat year-on-year in both reported and organic terms. Geographical performance was mixed: EMEA grew 5% organically while the Americas contracted 2% and Asia Pacific fell 5% in constant currency. The weaker Americas print reflects the intentional reduction in distributor stock levels that management flagged as a continuing headwind into Q4.

CooperSurgical, which covers fertility and women's healthcare products, grew 3% organically to $349.2 million. Its fertility segment was the standout, achieving 5% organic growth to reach $141.2 million. President and chief executive Al White said the fertility result was a highlight of the quarter alongside the HMRC tax outcome and record free cash flow generation, though he acknowledged that the CVI inventory correction "will continue to impact Q4."

During the quarter, the company repurchased $339.1 million of common stock, approximately 4.9 million shares at an average price of $69.16. The board also expanded the total share repurchase authorisation from $2 billion to $3 billion, leaving roughly $1.5 billion still available.

Market context and outlook

The contact lens market is a mature, oligopolistic segment dominated by CooperVision, Johnson and Johnson Vision Care, Alcon, and Bausch and Lomb. Growth rates across the category tend to track low-to-mid single digits organically, making CooperVision's flat print a mild disappointment even if the channel inventory work is self-imposed rather than demand-driven. The fertility market, by contrast, remains a structurally higher-growth segment; rising rates of IVF utilisation across Europe and Asia, combined with an expanding addressable population, give CooperSurgical a more favourable long-term growth backdrop.

CooperCompanies also confirmed it has completed a strategic review process and issued a separate release outlining actions intended to enhance shareholder value, though the earnings announcement did not detail those measures.

For Q4 2026, the company guided total revenue of $1.057 to $1.080 billion, with CVI expected to contract 0% to 2% organically and CooperSurgical to grow 4% to 6% organically. Non-GAAP diluted EPS guidance for Q4 stands at $1.05 to $1.09. Full-year fiscal 2026 revenue guidance was set at $4.229 to $4.252 billion, implying 2% to 3% organic growth, with full-year non-GAAP EPS of $4.51 to $4.55. The company reaffirmed its longer-term target of generating more than $2.2 billion in cumulative free cash flow across fiscal years 2026 through 2028.

Sector

Topic

Geography